BeOne Medicines Ltd. (ONC) operating KPIs
ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/302313% above fair value
$370.33−1.23 (-0.33%)
Close on Oct 30, 2026Market cap $42.11BP/E 66.2Yield –
BeOne Medicines external R&D — TEVIMBRA (tislelizumab, Anti-PD-1) ($M) ($M)
Form 8-K EX-99.1 SSE STAR Market Annual Reports (688235.SS)
Latest, FY2025
56.2
Period ended Dec 31, 2025
Change on a year earlier
-18.2%
68.7 in FY2024
History
9 years
Since FY2017
Sources
7
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | External R&D — TEVIMBRA (tislelizumab, Anti-PD-1) ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 56.2 | -18.2% | 8-K STAR Report (2026-04-14, 0001651308-26-000008) ↗ |
| FY2024 | Dec 31, 2024 | 68.7 | -18.0% | 8-K STAR Report (2026-04-14, 0001651308-26-000008) ↗ |
| FY2023 | Dec 31, 2023 | 83.8 | -5.8% | 8-K STAR Report (2025-04-28, 0001651308-25-000057) ↗ |
| FY2022 | Dec 31, 2022 | 88.9 | -45.8% | 8-K STAR Report (2024-04-26, 0001651308-24-000043) ↗ |
| FY2021 | Dec 31, 2021 | 164 | -24.0% | 8-K STAR Report (2023-04-25, 0001651308-23-000061) ↗ |
| FY2020 | Dec 31, 2020 | 216 | +12.4% | 8-K STAR Report (2022-04-28, 0001651308-22-000058) ↗ |
| FY2019 | Dec 31, 2019 | 192 | +51.0% | 8-K STAR Report (2021-11-16, 0001651308-21-000229) ↗ |
| FY2018 | Dec 31, 2018 | 127 | +175.0% | 8-K STAR Report (2021-11-16, 0001651308-21-000229) ↗ |
| FY2017 | Dec 31, 2017 | 46.2 | – | 8-K STAR Report (2021-01-29, 0001104659-21-009496) ↗ |
Cite this data
StockData. (2026). BeOne Medicines External R&D — TEVIMBRA (tislelizumab, Anti-PD-1) ($M) ($M), annual FY2017–FY2025 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/rd_mol_tevimbra
See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.